Status: Recruiting
Testing Use of Topical Imipramine in Reducing Ultraviolet B Induced Microvesicle Particle Release in Photosensitive Subjects
The purpose of this study is three-fold. First, researchers will assess whether subjects who have clinically abnormal reactions to sunlight (photosensitivity) have increased levels of microvesicle particles (MVP) following ultraviolet B (UVB) treatment to localized area of skin. Second, researchers will assess if topical application of the medicine imipramine will block UVB-induced MVP release. Third, researchers will assess if the topical cream will block UVB-induced increased erythema reactions (reddening of the skin).
Participants needed: 40
Trial details
Phase: Phase 1Age: 18-50Biological sex: AllType: InterventionalSponsor: Wright State UniversityUpdated: Jan 27, 2025Locations: 1
Eligibility criteria
Female and Male adult subjects age 18 to 50 [+5]
Underlying diseases that could affect wound healing (e.g., uncontrolled diabetes... [+8]